PeerVoice Clinical Pharmacology Audio

Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Silvia Stacchiotti, MD / Michiel van de Sande, MD, PhD - Surgical Interventions and Systemic Innovations: Collaborative Approaches to Tenosynovial Giant Cell Tumour as Pharmacological Advances Emerge

David Alain Wohl, MD - From Guidelines to Ground Truth: The Reality of Rapid ART in the Real World

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Sven Francque, MD, PhD - The Gastroenterologist’s Guide to Finding and Managing MASH With Fibrosis: Practical Strategies for Everyday Practice

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

Javier Ampuero, MD, PhD - Making MASH a Priority in Our Gastroenterology Practices: Why We Should and How We Can

Colin M. Dayan, MA, MBBS, FRCP, PhD - Innovation Through Immunomodulation: The Practicalities of Delaying the Progression of Type 1 Diabetes

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

Austin Kulasekararaj, MD, MRCP, FRCPath - From Life-Threatening to Life-Optimised: The Evolving Management of Paroxysmal Nocturnal Haemoglobinuria Across the Complement Cascade

Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

Cristina Saura Manich, MD, PhD - First-Line Treatment of HER2-Positive Metastatic Breast Cancer: Could Investigational Approaches Improve on Current Standard of Care?

David Kavanagh, MBChB, PhD, FRCP - A Clinically Considered Real-World Case Series: Practice Essentials From Biopsy To Diagnosis in Immune-Mediated Glomerular Diseases

Yohei Doi, MD, PhD - Know the Risk, Act on Evidence: Strategic Interventions in COVID-19 Care of High-Risk Patients

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Jörn M. Schattenberg, MD - Cases in Contemporary MASH Management: Expert Insights on the Practical Integration of Disease-Specific Pharmacotherapy

Naim Alkhouri, MD, FAASLD, DABOM - Don’t Wait, and Look Beyond Weight: The Growing Case for Urgent and Comprehensive Management of MASH

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition